Spruce Biosciences (SPRB) Accumulated Expenses (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Accumulated Expenses of $8.1 million for Q1 2026, down 34.89% year-over-year from $12.4 million in Q1 2025, and down 11.4% quarter-over-quarter from $9.1 million in Q4 2025.
Spruce Biosciences (SPRB) Accumulated Expenses (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Accumulated Expenses for 8 consecutive years, with $8.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 34.89% year-over-year to $8.1 million; the TTM figure through Mar 2026 stood at $8.1 million (down 34.89% YoY), while the FY2025 annual figure was $9.1 million, down 25.84% from the prior year.
- Accumulated Expenses eased to $8.1 million in Q1 2026 per SPRB's latest filing, from $9.1 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $14.6 million in Q4 2023 and bottomed at $893000.0 in Q2 2022.
- Historically, Accumulated Expenses has averaged $8.7 million across 5 years, with a median of $8.7 million in 2023.
- On a YoY basis, Accumulated Expenses climbed as much as 752.73% in 2022 and fell as far as 81.75% in 2022.
- Spruce Biosciences' Accumulated Expenses stood at $9.4 million in 2022, then surged by 55.34% to $14.6 million in 2023, then retreated by 15.55% to $12.3 million in 2024, then slipped by 25.84% to $9.1 million in 2025, then fell by 11.4% to $8.1 million in 2026.
- Business Quant data shows SPRB's Accumulated Expenses at $8.1 million in Q1 2026, $9.1 million in Q4 2025, and $7.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.25 Mn |
| Mar 31, 2026 | 8.10 Mn |
| Dec 31, 2025 | 9.14 Mn |
| Sep 30, 2025 | 7.50 Mn |
| Jun 30, 2025 | 6.31 Mn |
| Mar 31, 2025 | 12.44 Mn |
| Dec 31, 2024 | 12.33 Mn |
| Sep 30, 2024 | 7.74 Mn |
| Jun 30, 2024 | 10.68 Mn |
| Mar 31, 2024 | 11.97 Mn |
| Dec 31, 2023 | 14.60 Mn |
| Sep 30, 2023 | 11.62 Mn |
| Jun 30, 2023 | 1.68 Mn |
| Mar 31, 2023 | 8.72 Mn |
| Dec 31, 2022 | 9.40 Mn |
| Sep 30, 2022 | 8.60 Mn |
| Jun 30, 2022 | 893,000.00 |
| Mar 31, 2022 | 6.46 Mn |
| Dec 31, 2021 | 6.05 Mn |
| Sep 30, 2021 | 1.01 Mn |